AFT Pharmaceuticals (AFT Pharmaceuticals) ROCE % : 77.27% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is AFT Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. AFT Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2024 was 77.27%.

AFT Pharmaceuticals ROCE % Historical Data

The historical data trend for AFT Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AFT Pharmaceuticals ROCE % Chart

AFT Pharmaceuticals Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

61.83

18.04

25.05

17.71

22.38

AFT Pharmaceuticals Quarterly Data
	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
ROCE %	Get a 7-Day Free Trial												70.56	16.20	70.81	13.51	77.27

AFT Pharmaceuticals ROCE % Calculation

AFT Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	15.636	/	( ( (91.908 - 24.69)	+	(100.521 - 28.022) )	/ 2 )
	=	15.636	/	( (67.218	+	72.499)	/ 2 )
	=	15.636	/	69.8585
	=	22.38 %

AFT Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Sep. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Sep. 2023 )		(Q: Mar. 2024 )
	=	53.34	/	( ( (94.23 - 28.674)	+	(100.521 - 28.022) )	/ 2 )
	=	53.34	/	( ( 65.556	+	72.499 )	/ 2 )
	=	53.34	/	69.0275
	=	77.27 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

AFT Pharmaceuticals (OTCPK:AFTPF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

AFT Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of AFT Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

AFT Pharmaceuticals (AFT Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AFT Pharmaceuticals Ltd (OTCPK:AFTPF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

AFT:New Zealand AFP:Australia

Address

129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622

Website

https://www.aftpharm.com

AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Aqueous cream, Calci-tab, Maxigesic, Cromo-fresh, Crystaderm, Crytawash, Ellgy plus, Emulsifying ointment, and others. The group has four operating segments based on geographical location being, Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia which includes the sales and distribution activity relating to the Australian market.